BioNTech Q2 2026 net loss widens to €820.8 million; revenue drops 59.52% to €105.6 million vs Q2 2025

• BioNTech posted IFRS Q2 revenue of €105.6 million, down 59.52% year over year, while IFRS net loss widened to €820.8 million.
• IFRS diluted loss per share deepened to €3.24; IFRS R&D expenses climbed to €551 million and SG&A expenses rose to €197.8 million.
• Cash, cash equivalents and security investments totaled €16.6 billion at June 30; a $1 billion ADS buyback began in May.
• Full-year 2026 revenue guidance was cut to €1.6 billion-€1.9 billion; adjusted R&D guidance was lowered to €2 billion-€2.3 billion.
• Guido Oelkers was named incoming CEO, due to take office by Feb. 1, 2027; the pipeline includes 14 pivotal trials, including new late-stage starts for pumitamig.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040645OMX_____CNEWS_EN_GNW1001255973_en) on August 04, 2026, and is solely responsible for the information contained therein.